But, of course, Kenvue, with annual net sales of $15.6 billion (midpoint analyst estimate for 2023), cannot be compared with industry giants such as The Procter & Gamble Company (PG, net sales of $82 billion in fiscal 2023). In its prospectus, Kenvue says it holds “leadership positions” in the consumer health market, owning top brands in pain management (Tylenol), facial care (Neutrogena), mouthwash (Listerine), and many other categories. The benefit for investors is that the business has some brand power, which in turn could give it pricing power and make it a potentially resilient company to invest in amid inflation. Strong diversification is one of the things investors can expect to get from owning the healthcare stock.
From gently cleaning tiny fingers during a baby’s first bath to protecting the vitality of your skin to soothing aches and pains — our products deliver safe, effective, everyday care at every stage of life. Annual sales growth through 2025 is projected to be about 3% to 4% globally, according to the filing. J&J plans to distribute the remaining shares of common stock to its shareholders later this year. Kenvue’s debut also marks the largest restructuring in J&J’s 135-year history.
- Annual sales growth through 2025 is projected to be about 3% to 4% globally, according to the filing.
- This year’s Global Inclusion, Diversity & Equity Annual Report highlights the progress Medtronic is making to drive real impact toward zero barriers to opportunity.
- And products in the essential health division, including baby products, mouthwash and dental rinses, sanitary protection and wound care, saw $4.6 billion in net sales, representing 31% of all-in revenue.
- The test will be used in conjunction with clinical and radiological evaluation of a patient by physicians, to improve the referral process and better inform clinical decision making workflows.
- The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. This not only generates investment capital for the healthcare https://g-markets.net/ technology company but also drives value for shareholders and investors. As with any market, you need to know what to look for if you’re to make smart decisions.
Kenvue Has Gone Public: Should You Buy the Stock?
The Consumer Health segment generated revenue of $14.6 billion in Full-Year 2021 and, following the planned separation, Kenvue would generate sales in over 100 countries, driven by world-class innovation capabilities and demonstrated business momentum. Usage of the new company logo and corporate brand identity will be effective upon completion of the planned separation. More information regarding Kenvue, including the company’s board of directors and financial transaction information will be available at a later date. Kenvue expects to pay a quarterly cash dividend of about 20 cents per share starting with the third quarter, which ends Oct. 1.
Could the Silver Price Really Hit US$100 per Ounce?
So, Kenvue products are considered necessities & essential parts of our everyday lives and will be for the foreseeable future. The company also warns investors that it may continue to be subject to claims that fall outside of the previously indemnified Talc-Related Liabilities given that Kenvue still sells talc products in countries around the globe. The sale of these products will be discontinued in 2023, but the company still warns that litigation that isn’t covered by the indemnity remains a possibility and could adversely impact the newly-formed business.
Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.
Investing News NetworkYour trusted source for investing success
For Q2 2023, management was able to surprise positively on both adjusted earnings per share (EPS, 7% surprise) and net sales (1.3% surprise). For the third quarter, the company missed analysts’ EPS estimates by a hair (-1.4%), but delivered net sales in line with estimates. Kenvue has already been involved in seven talc lawsuits (at least) since the start of last month, according to Reuters. The danger is that even a handful of claims could potentially yield devastating results for Kenvue, as its assets and revenue stream won’t nearly be the size of Johnson & Johnson’s.
Spin-off and IPO
This strong, distinctive color works in harmony with the multicolored palette of the company’s portfolio of well-known brands. It expects annual sales growth through 2025 to be about 3% to 4% globally, according to the filing. Furthermore, the company currently has a conservative payout ratio and a strong balance sheet that management has focused on de-leveraging in 2023. They also initiated a buyback program in Q3, and I expect management to take advantage in 2024 buying back shares, returning additional cash to shareholders. KVUE currently has a P/E of less than 16x, below the sector median of nearly 18x, signaling it may be undervalued. As a new spin-off and with the soft outlook management issued during Q4 earnings, I suspect the stock’s price will trade around these levels for some time.
His areas of expertise involve electric vehicle (EV) stocks, green energy and NFTs. On the date of publication, Samuel O’Brient did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. The recommended dose of BIJUVA® is a single capsule, taken orally, each evening with food. BIJUVA® should be used for a duration consistent with treatment goals and the benefits and risks for the individual woman. Postmenopausal women should be periodically re-evaluated as clinically appropriate to determine if treatment is still necessary.
Kenvue debuts with strong second quarter 2023 results
These actions have bolstered positions in Self Care, Skin Health and Essential Health. One risk investors face holding Kenvue is the short track record of the spun-off business. Because of this, any uncertainty surrounding the yandex trade company will likely cause the share price to experience volatility. I think the market is still unsure what to make of them, but as previously mentioned, if you’re a long-term investor, then Kenvue is definitely worth a look.
Kenvue is a compact yet powerful name that stands for the fusion of knowledge and vision. “Ken” is an English word meaning “to know,” and “vue” is French, referring to insight. And, even more fitting, “K” comes after “J” in the English alphabet, a subtle nod to Kenvue as the name of the consumer health sector’s next chapter. Then, with an eye towards global growth, we created the brand’s Chinese name, which successfully achieved phonetic similarity with the English name. And products in the essential health division, including baby products, mouthwash and dental rinses, sanitary protection and wound care, saw $4.6 billion in net sales, representing 31% of all-in revenue. As the company presented its first results as an independent company last July, there is of course not much history to analyze.
However, considering that CEO Mongon has been with the parent company for 23 years and has led the former Consumer Health segment since 2019, I view JNJ’s tradition of at least meeting estimates as a reasonable expectation for Kenvue. In addition, its recession-resistant business model and low demand volatility contribute their fair share to what I believe could become a “sleep well at night” company. JNJ’s Consumer Health segment has seen some margin expansion in recent years (Figure 4), but of course there is still room for improvement, especially in terms of cash profitability (estimated free cash flow margin of 17%). Note that I have adjusted the profit figures used in the calculation for litigation-related expenses and gains from divestitures. I consider the adjustment for the former in particular to be very important, as Johnson & Johnson retains the majority of talc-related claims (detailed analysis here) – Kenvue will only be responsible for claims outside the US or Canada. Of course, the point can be made that now that Kenvue is independent of its parent company and can freely allocate its resources, a return to more meaningful growth is a reasonable expectation.
Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to our Terms of Service in the Legal Notice. You should view the Media section in order to receive the most current information made available by Kenvue.